Gaggar Anuj 4

What Happened

• Anuj Gaggar, Chief Medical Officer of Assembly Biosciences (ASMB), was granted 26,000 restricted stock units (RSUs) on March 29, 2026. The Form 4 reports the acquisition price as $0.00 (typical for RSU awards); no cash purchase or open-market sale occurred. This is an equity compensation grant rather than a purchase or sale of existing shares.

Key Details

• Transaction date: 2026-03-29; Filing date: 2026-03-31 (filed within the normal reporting window).
• Reported price: $0.00 (award/grant — transaction code A).
• Vesting: RSUs vest in four equal annual installments on March 29 of 2027, 2028, 2029 and 2030 (vesting requires continuous service).
• Contingency: The disclosed 26,000 RSUs represent 65% of the officer’s annual equity grant; the remaining 35% is contingent on stockholder approval of an increase in shares available under the company’s 2018 Stock Incentive Plan.
• Additional note: Filing also references 2,000 shares acquired under the company’s Employee Stock Purchase Plan on Nov 14, 2025 (background holding, not part of this grant).
• Shares owned after the grant were not specified in the provided excerpt.

Context

• RSUs are a common form of executive compensation that convert into shares if and when they vest; they are not an immediate purchase or sale and therefore do not directly signal buying/selling sentiment.
• Because part of the grant is contingent on shareholder approval to expand the share pool, some of the award may not vest unless that approval is obtained.
• No tax withholding or immediate cashless sale is indicated in this filing.